Precision Medicine in Oncology® | Specialty

EGFR Inhibitors as Adjuvant Therapy in NSCLC

October 20th 2018

Promising Treatment Combinations in EGFR+ NSCLC

October 20th 2018

Emerging EGFR Inhibitors in NSCLC

October 20th 2018

Managing Disease Progression in EGFR+ NSCLC

October 20th 2018

Overcoming Resistance to EGFR Inhibitors in NSCLC

October 20th 2018

Osimertinib For Uncommon EGFR Mutations in NSCLC

October 20th 2018

Significance of FLAURA in EGFR+ NSCLC

October 20th 2018

Personalized Medicine in a Time of Depersonalized Patient-Doctor Relationships

September 11th 2018

Gagandeep Brar, MD, reflects on patient interactions that she has encountered throughout her fellowship.

Surgical Trials Highlight Complexity of Interpreting Randomized Data

August 31st 2018

In recent years there has been much discussion about the serious limitations of the conduct and interpretation of randomized trials examining the utility of antineoplastic drug therapy.

Dr. Brown on the Importance of Genetic Testing in Ovarian Cancer

August 30th 2018

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of genetic testing in patients with ovarian cancer.

Dr. Shiller on Hereditary Predisposition to Cancer

August 30th 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses a patient’s hereditary predisposition to cancer.

Dr. Brown on the Adoption of Genetic Testing

August 22nd 2018

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the adoption of genetic testing into routine clinical practice.

Personalized Medicine Continues to Evolve in Oncology

August 21st 2018

Leonid Shunyakov, MD, discusses the impact genomics has on personalized therapy and the roster of available therapies that continues to grow as a result of identifiable genomic drivers.

Expanded Scalp Cooling Approval Offers Patients More Choices

August 20th 2018

An expanded indication for the Paxman Scalp Cooling System to include the prevention of chemotherapy-related alopecia in patients with solid tumors will increase the population eligible for the therapy dramatically and allow for more personalized treatment options.

Dr. Bunn on TMB as a Biomarker in Small Cell Lung Cancer

August 15th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses tumor mutational burden as a biomarker in small cell lung cancer.

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

August 10th 2018

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

Dr. Aisner on the Limitations of Molecular Profiling

August 10th 2018

Dara L. Aisner, MD, PhD, associate professor in the department of Pathology at the University of Colorado School of Medicine, discusses the limitations of molecular profiling.

Optimal Sequence of EGFR TKI Therapy for NSCLC Under Investigation

July 29th 2018

Recent positive clinical trial data have provided the oncology community with several sequencing strategies for patients with EGFR-mutant non-small cell lung cancer.

Mok Debates First-Line Versus Second-Line TKI Use in Oncogene-Driven NSCLC

July 29th 2018

The use of frontline versus second-line tyrosine kinase inhibitor use is controversial in many oncogene-driven non-small cell lung cancers.

Dr. Wakelee on Recent Advancements in EGFR-Mutant NSCLC

July 28th 2018

Heather Wakelee, MD, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest therapeutic developments in EGFR-mutant non-small cell lung cancer.